Biotech entity
ANKTIVA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 35-day span, the pace is roughly 0.4 stories per week. Source depth averages 2.5 original sources per story, versus 3.4 across the same-window beat baseline.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ANKTIVA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 35-day span, the pace is roughly 0.4 stories per week. Source depth averages 2.5 original sources per story, versus 3.4 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.1. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Biotech stories mentioning ImmunityBio across the period from February 18, 2026 to March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 452 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ImmunityBio. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Warning
FDA flags misleading claims made by Patrick Soon-Shiong regarding off-label uses of Anktiva.
FDA Approval
Anktiva is approved for BCG-unresponsive NMIBC in combination with BCG.
Initial Rejection
FDA issues a Complete Response Letter (CRL) for Anktiva due to manufacturing deficiencies.
The FDA has issued a formal warning to Dr. Patrick Soon-Shiong, the billionaire founder of ImmunityBio, regarding misleading statements made about the company’s bladder cancer therapy, Anktiva. The regulator flagged claims made during a podcast that suggested the drug could treat a broader range of cancers than its current approval allows.
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Source: The Motley Fool · AOL.com
ImmunityBio is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
